OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.830
-0.080 (-4.19%)
At close: Jul 3, 2025, 1:00 PM
1.870
+0.040 (2.19%)
After-hours: Jul 3, 2025, 5:00 PM EDT
OS Therapies Employees
As of December 31, 2024, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,654,556
Market Cap
54.30M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OSTX News
- 2 days ago - OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Business Wire
- 5 days ago - OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference - Business Wire
- 11 days ago - OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma - Business Wire
- 12 days ago - OS Therapies Announces Warrant Exercise Inducement & Exchange Offer - Business Wire
- 25 days ago - OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma - PRNewsWire
- 4 weeks ago - OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma - Business Wire
- 7 weeks ago - OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 7 weeks ago - OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma - Business Wire